Clinical trial / 2025
Cocoa extract supplementation did not reduce overall incident hypertension in older adults, though it lowered risk in those with baseline systolic BP <120 mm Hg.
In the COSMOS trial, 8,905 older adults free of baseline hypertension were randomized to daily cocoa extract (500 mg/d cocoa flavanols with 80 mg/d [-]-epicatechin) or placebo. Over a median follow-up of 3.4 years, cocoa extract did not significantly reduce incident hypertension overall (7.1 vs 7.4 per 100 person-years; HR 0.96 [95% CI, 0.88-1.05]). However, in subgroup analysis, cocoa extract reduced incident hypertension among participants with baseline systolic BP <120 mm Hg (HR 0.76 [95% CI, 0.64-0.90]), but not among those with baseline systolic BP of 120 to 139 mm Hg (HR 1.05 [95% CI, 0.93-1.18]; P-interaction=0.002).
- Study type
- 2x2 factorial, double-blind, placebo-controlled randomized clinical trial
- Who was studied
- 8,905 older adults (women aged >=65, men aged >=60) free from baseline hypertension (mean age 71.1 years, 59% women)
- What was measured
- Incident hypertension (self-reported physician diagnosis, medication initiation, or elevated blood pressure)
THE PAPER
Long-Term Effect of Cocoa Extract Supplementation on Incident Hypertension.
Hamaya R, Li S, Lau J, Allison M, Haring B, Shadyab AH, Matthew N, Martin LW, Rist PM, Manson JE, Sesso HD, COSMOS Research Group. Hypertension, 2025.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.